Alcresta Announces Agreement with Cystic Fibrosis Foundation Therapeutics to Develop Point-of-Care Nutritional Products
NEWTON, Mass., Apr 17, 2014 (BUSINESS WIRE) — Alcresta®, a leading medical nutrition company developing innovative enzyme-based products for individuals with unique nutritional needs battling acute conditions or chronic diseases, today announced the company has signed an agreement with Cystic Fibrosis Foundation Therapeutics (CFFT) to accelerate the development of Alcresta’s enzyme-based point-of-care products to support the nutritional status of people with cystic fibrosis (CF). CFFT is the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation.
More than 90 percent of people with CF have a compromised pancreas and need enzyme-based nutritional products to digest and absorb vitamins and nutrients. To address these challenges, people with compromised pancreatic or gastrointestinal function, including people with CF, consume nutritional drinks and use tube feedings to supplement their diet. This agreement allows Alcresta to accelerate the development of its nutrition technology and advance point-of-care products designed to address the specific needs of the CF population and others with unique nutritional needs by improving absorption of beneficial fatty acids and aiding in overall caloric intake.
According to the CF Foundation’s patient data report, a relationship has been established in CF between good health outcomes and patients’ nutritional levels, reinforcing the...
Source: Cystic Fibrosis Worldwide Blog - Category: Respiratory Medicine Authors: Webmaster Tags: Research and Discovery Source Type: blogs
More News: Blogging | Cystic Fibrosis | Gastroenterology | Health | National Institutes of Health (NIH) | Nutrition | Pancreas | Respiratory Medicine | Science | Vitamins